Reviewing Audentes Therapeutics Inc. (BOLD)’s and DelMar Pharmaceuticals Inc. (NASDAQ:DMPI)’s results

Audentes Therapeutics Inc. (NASDAQ:BOLD) and DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Audentes Therapeutics Inc. 28 -1.07 37.36M -3.79 0.00
DelMar Pharmaceuticals Inc. 1 0.00 9.70M -3.36 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Audentes Therapeutics Inc. and DelMar Pharmaceuticals Inc.

Profitability

Table 2 provides us Audentes Therapeutics Inc. and DelMar Pharmaceuticals Inc.’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Audentes Therapeutics Inc. 131,410,481.89% -40.8% -37.4%
DelMar Pharmaceuticals Inc. 1,442,593,694.23% 264.9% -173.6%

Liquidity

The current Quick Ratio of Audentes Therapeutics Inc. is 14.3 while its Current Ratio is 14.3. Meanwhile, DelMar Pharmaceuticals Inc. has a Current Ratio of 2 while its Quick Ratio is 2. Audentes Therapeutics Inc. is better positioned to pay off its short-term and long-term debts than DelMar Pharmaceuticals Inc.

Analyst Ratings

The next table highlights the shown recommendations and ratings for Audentes Therapeutics Inc. and DelMar Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Audentes Therapeutics Inc. 0 4 2 2.33
DelMar Pharmaceuticals Inc. 0 0 1 3.00

$48.57 is Audentes Therapeutics Inc.’s average price target while its potential downside is -18.19%. Competitively the average price target of DelMar Pharmaceuticals Inc. is $2, which is potential 201.39% upside. The data provided earlier shows that DelMar Pharmaceuticals Inc. appears more favorable than Audentes Therapeutics Inc., based on analyst view.

Insider & Institutional Ownership

The shares of both Audentes Therapeutics Inc. and DelMar Pharmaceuticals Inc. are owned by institutional investors at 0% and 17.5% respectively. Audentes Therapeutics Inc.’s share owned by insiders are 1.3%. Competitively, 0.6% are DelMar Pharmaceuticals Inc.’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Audentes Therapeutics Inc. -1.57% 1.22% 4.6% 62.23% 5.7% 82.55%
DelMar Pharmaceuticals Inc. 17.88% 39.05% -51.89% -47.95% -67.04% -47.94%

For the past year Audentes Therapeutics Inc. had bullish trend while DelMar Pharmaceuticals Inc. had bearish trend.

Summary

DelMar Pharmaceuticals Inc. beats Audentes Therapeutics Inc. on 7 of the 12 factors.

Audentes Therapeutics, Inc., a biotechnology company, focuses on developing and commercializing gene therapy products for patients suffering from diseases caused by single gene defects in the United States. The company is developing AT132 for the treatment of X-linked myotubular myopathy; AT342 for the treatment of crigler-najjar syndrome type 1; AT982 for the treatment of pompe disease; and AT307 for the treatment of the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia. Audentes Therapeutics, Inc. has a collaboration with the University of Pennsylvania for the treatment of Crigler-Najjar. The company was founded in 2012 and is headquartered in San Francisco, California.

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. Its product candidate includes VAL-083, a small-molecule chemotherapeutic agent, which has completed Phase I/II study to evaluate the safety, tolerability, pharmacokinetics, and anti-cancer activity in patients with glioblastoma multiforme, a form of brain cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical Company for the manufacture and sale of VAL-083 in China; collaboration agreement with the University of Texas MD Anderson Cancer Center; and collaboration agreement with Accurexa Inc. to develop a novel formulation for the local delivery of combination chemotherapy for the treatment of brain cancer and other solid tumors. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Vancouver, Canada.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.